Targeted tilianin lipid nanoparticles for the treatment of atherosclerosis through remodeling lesional macrophage phenotype
Yaoyao Luo(Sichuan University), Xiangrong Song(Sichuan University), Shugang Qin(Sichuan University), Shengbin Liu(Sichuan University), Yongxian Hu(University of Akron), Min Sun(First Affiliated Hospital of Shihezi University Medical College), Huiling Yang(Shihezi University), Guohong Li(Sichuan University), Wanqin Zeng(Sichuan University), Xinchun Wang(First Affiliated Hospital of Shihezi University Medical College), Zhaohui Jin(XinHua Hospital), Zhongshan He(University of Virginia), Xiaoling Yin(Sichuan University), Yupei Zhang(Northwestern Polytechnical University)
Cited by 2
Related Papers
Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics
|Signal Transduction and Targeted Therapy|2022|1.3k
mRNA-based therapeutics: powerful and versatile tools to combat diseases
|Signal Transduction and Targeted Therapy|2022|710
Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment
|Nature Nanotechnology|2024|148